Oppenheimer Maintains Outperform on Alumis, Raises Price Target to $55

3/30/2026
Impact: 75
Healthcare

Oppenheimer analyst Jeff Jones has maintained an Outperform rating on Alumis (NASDAQ: ALMS) and raised the price target from $50 to $55. This adjustment reflects a positive outlook for the company's performance in the market.

AI summary, not financial advice

Share: